What is Immunocore?
Immunocore is a British clinical-stage biotechnology firm established in 2008, specializing in the development of innovative biological drugs. The company leverages its proprietary soluble T-cell receptor technology to target a range of challenging diseases, including cancer, infectious diseases, and autoimmune disorders. Headquartered in Milton, United Kingdom, Immunocore is focused on translating cutting-edge scientific research into therapeutic solutions for unmet medical needs.
How much funding has Immunocore raised?
Immunocore has raised a total of $822.1M across 4 funding rounds:
Series A
$320M
Series B
$130M
Series C
$75M
Stock Offering
$297.1M
Series A (2015): $320M with participation from woodford investment management, eli lilly and company, RTW Funds, and Malin Corporation plc
Series B (2020): $130M led by JDRF T1D Fund, Bill & Melinda Gates Foundation, WuXi AppTec, Rock Springs Capital, General Atlantic LLC, Eli Lilly and Company, China Construction Bank, Terra Magnum Capital Partners, and RTW Investments
Series C (2021): $75M supported by BlackRock
Stock Issuance/Offering (2021): $297.1M, investors not publicly disclosed
Key Investors in Immunocore
woodford investment management
Woodford Investment Management is an investment firm that likely focuses on identifying and backing companies with high growth potential, particularly within the life sciences sector, given its participation in Immunocore's Series A round.
Eli Lilly and Company
Eli Lilly and Company, a global biopharmaceutical leader, invests in companies that align with its strategic interests in developing novel therapeutics for major diseases, including oncology and immunology.
RTW Investments
RTW Investments is a life sciences investment firm dedicated to advancing biotech and medtech innovation, providing capital and strategic support to companies aiming to transform patient care.
What's next for Immunocore?
The substantial enterprise-level funding and strategic investment received by Immunocore indicate a strong investor confidence in its therapeutic pipeline and technological platform. This capital infusion is expected to accelerate the company's clinical development programs, potentially advancing its lead candidates through late-stage trials and towards commercialization. Immunocore's focus on oncology, infectious diseases, and autoimmune conditions positions it to address significant global health challenges, with future growth likely driven by successful clinical outcomes and strategic partnerships.
See full Immunocore company page
